ASH Conference Media

Saturday 7th December

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis – Catalyst Trial Results
Download Poster – 1_CATALYST-ASH-Poster-2019.pdf

Lenalidomide Maintenance Prolongs Progression-Free Survival and Does Not Impact the Aggressiveness of Clinical Relapse: Data from Long-Term Follow up of the Myeloma XI Trial
Download Poster – 2_TCR-FINAL.pdf

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial
Download Poster – 3_GHJ-FINAL.pdf


Sunday 8th December

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia – Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)
Download Poster – 4_OPTIMUM_ASH2019.pdf

Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV
Download Poster – 5_FITNESS_ASH2019.pdf

Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance
Download Poster – 6_John-SPM-031219-FINAL.pdf


Monday 9th December

Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma – Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial
Download Poster – 7_MUKSeven_ASH2019.pdf

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
Download Poster – 8_ASH-Sex-FINAL.pdf